This study aimed to test associations between genetic risk factors for AD (beyond APOE) and biomarkers reflecting abnormal metabolism of Aβ, soluble phosphorylated tau (P-tau), and neurodegeneration to understand different aspects of AD pathophysiology using CSF biomarkers as proxies for relevant brain changes. Here, MAPT is linked to Alzheimer disease.